The Journal of Experimental Medicine
Avanti Polar Lipids, Inc.
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

Published online 28 February 2005 doi:10.1084/jem.20042432
Rockefeller University Press, 0022-1007 $8.00
JEM, Volume 201, Number 5, 695-701
This Article
Right arrow Full Text
Right arrow Full Text (PDF, 1028K)
Right arrow PPT slides of all figures
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pasquier, B.
Right arrow Articles by Latour, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pasquier, B.
Right arrow Articles by Latour, S.
Related Collections
Right arrowRelated Article
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

BRIEF DEFINITIVE REPORT

Defective NKT cell development in mice and humans lacking the adapter SAP, the X-linked lymphoproliferative syndrome gene product

Benoit Pasquier1, Luo Yin4, Marie-Claude Fondanèche1, Francis Relouzat1, Coralie Bloch-Queyrat1, Nathalie Lambert1,2, Alain Fischer1,3, Geneviève de Saint-Basile1, and Sylvain Latour1

1 Laboratoire du Développement Normal et Pathologique du Système Immunitaire, Unité INSERM 429
2 Centre d'Étude des Déficits Immunitaires, Hôpital Necker Enfants-Malades, 75015 Paris, France
3 Unité d'Immunologie-Hématologie Pédiatrique, Hôpital Necker Enfants-Malades, 75015 Paris, France
4 International Agency for Research on Cancer, 69372 Lyon, France

CORRESPONDENCE Sylvain Latour: latour{at}necker.fr

SAP is an adaptor protein expressed in T cells and natural killer cells. It plays a critical role in immunity, as it is mutated in humans with X-linked lymphoproliferative syndrome (XLP), a fatal immunodeficiency characterized by an abnormal response to Epstein-Barr virus (EBV) infection. SAP interacts with the SLAM family receptors and promotes transduction signal events by these receptors through its capacity to recruit and activate the Src kinase FynT. Because it has been previously established that FynT is selectively required for the development of NKT cells, we examined NKT cells in SAP-deficient mice and in humans with XLP. In the absence of SAP, the development of NKT cells is severely impaired both in mice and in humans. These results imply that SAP is a potent regulator of NKT cell development. They also identify for the first time a defect in NKT cells associated with a human primary immunodeficiency, revealing a potential role of NKT cells in the immune response to EBV.



Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?

Related Article

NKT cells depend on SAP
Heather L. Van Epps
J. Exp. Med. 2005 201: 662-663. [Full Text] [PDF]



This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS